HOME > ORGANIZATION
ORGANIZATION
- JPWA Chief Highlights Progress in Single-Product, Single-Price Trading
May 27, 2014
- MTPC, MSD Return to JPMA’s BOD
May 26, 2014
- Yearly NHI Price Revision Not Consistent with Growth Strategy: JPMA Exec
May 23, 2014
- Astellas Chair Nogimori Sworn in as Head of FPMAJ
May 22, 2014
- Dainippon Pres. Tada Elected New Chief of JPMA
May 22, 2014
- Market Share of Generic Drugs Based on New Calculation Method Rose to 44.9% in 3rd Quarter of FY2013: JGA
May 19, 2014
- Quality Control Essential for Preventing Disruptions in Supplies of Generic Drugs; Double-Sourcing Not Enough
May 7, 2014
- Medwatcher Calls for Making Physician Payment Disclosure Obligatory by Law
May 2, 2014
- JPMA Issues New Notification on Promotional Rules Related to Data Presented at Scientific Conferences, Lecture Meetings
May 1, 2014
- Adoption of CDISC Standards Will Be Daunting Task: JPMA Regulatory Affairs Head
April 28, 2014
- JPMA Announces New Guidelines on Support for Clinical Research
April 24, 2014
- Japan Should Stick to Current Mixed Care Scheme: Kenporen Exec Shirakawa
April 22, 2014
- JMA Pres. Yokokura Voices Opposition to Proposed Mixed Care System, Annual Drug Price Revisions
April 21, 2014
- Membership Suspension Appropriate for Novartis Pharma Involvement in SIGN Trial: JPMA
April 21, 2014
- Dainippon’s Takada to Head JPMA Public Affairs Committee
April 18, 2014
- EFPIA Poised to Present Plan for Japan-Version IMI by Year-End
April 16, 2014
- Funding for Investigator-Led Studies Should Be Based on Contracts: EFPIA Japan
April 16, 2014
- More Clinical Trial Sites Sharing Information Online: JMACCT
April 16, 2014
- NCVC Establishes Integrated Information Center to Collect Information on Cardiovascular Diseases from Around the Country
April 16, 2014
- APAC Agrees to Aim for Mutual Recognition of New Drug Review Results by 2020
April 15, 2014
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…